Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "DNA"

180 News Found

CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp
Biotech | January 25, 2023

CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp

OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program


Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData
News | January 12, 2023

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022


Moderna to acquire Oriciro Genomics
News | January 11, 2023

Moderna to acquire Oriciro Genomics

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines


Blacksmith announces merger with Forge Therapeutics
News | January 03, 2023

Blacksmith announces merger with Forge Therapeutics

To create leading company developing medicines targeting metalloenzymes


PM dedicates AIIMS Nagpur to the nation
Policy | December 12, 2022

PM dedicates AIIMS Nagpur to the nation

The hospital is being developed at a cost of more than Rs. 1,575 crore


Orchid Pharma reports positive EBIDTA in Q2
News | November 15, 2022

Orchid Pharma reports positive EBIDTA in Q2

The company is focussed on increasing the capacity utilizations while controlling costs


How nutrigenomics can help you plan an effective and healthy diet
Opinion | September 20, 2022

How nutrigenomics can help you plan an effective and healthy diet

Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.


Lonza and Touchlight collaborate on end-to-end mRNA offering
Biotech | September 07, 2022

Lonza and Touchlight collaborate on end-to-end mRNA offering

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology


Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
Diagnostic Center | August 20, 2022

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets